Abstract
Arginine vasopressin (AVP) is a cyclic nonapeptide synthesized exclusively by neurosecretory cells of the central nervous system (CNS). Two functionally distinct vasopressinergic systems can be defined based on differences in the sites of action and release of AVP. The peripheral vasopressinergic system encompasses the sites of action for AVP released into peripheral circulation (e.g. vascular smooth muscle, liver, kidney) from nerve terminals in the posterior pituitary. Peripherally circulating AVP is responsible for the classic endocrine functions ascribed to this neurohormone (e.g. vasoconstriction, glycogen metabolism, antidiuresis). The central vasopressinergic system, on the other hand, includes the sites of AVP synthesis and release within the CNS, where AVP acts as a neuromodulator / neurotransmitter regulating an array of CNS-mediated functions (e.g. learning and memory, neuroendocrine reactivity, social behaviors, circadian rhythmicity, thermoregulation, and autonomic function). Historically, pharmaceutical interest has focused on drug development efforts that sought to exploit the peripheral effects of AVP. Evidence, however, from clinical studies and animal models of CNS disorders has directly implicated disturbances in vasopressinergic activity in the pathophysiology of a number of human psychiatric disorders (mood, anxiety, and cognitive disorders). This review will examine the available evidence of central vasopressinergic system involvement in psychiatric disorders, and the potential opportunities for development of novel psychopharmaceuticals around this system will be discussed. Specific lines of evidence will be presented which rationalize each AVP receptor subtype (V1R or V1a, V2R, V3R or V1b) as a molecular target for particular psychiatric indications.
Keywords: vasopressin, depression, schizophrenia, alzheimer's, psychopharmaceutical
Current Pharmaceutical Design
Title: The Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development
Volume: 11 Issue: 2
Author(s): Robert H. Ring
Affiliation:
Keywords: vasopressin, depression, schizophrenia, alzheimer's, psychopharmaceutical
Abstract: Arginine vasopressin (AVP) is a cyclic nonapeptide synthesized exclusively by neurosecretory cells of the central nervous system (CNS). Two functionally distinct vasopressinergic systems can be defined based on differences in the sites of action and release of AVP. The peripheral vasopressinergic system encompasses the sites of action for AVP released into peripheral circulation (e.g. vascular smooth muscle, liver, kidney) from nerve terminals in the posterior pituitary. Peripherally circulating AVP is responsible for the classic endocrine functions ascribed to this neurohormone (e.g. vasoconstriction, glycogen metabolism, antidiuresis). The central vasopressinergic system, on the other hand, includes the sites of AVP synthesis and release within the CNS, where AVP acts as a neuromodulator / neurotransmitter regulating an array of CNS-mediated functions (e.g. learning and memory, neuroendocrine reactivity, social behaviors, circadian rhythmicity, thermoregulation, and autonomic function). Historically, pharmaceutical interest has focused on drug development efforts that sought to exploit the peripheral effects of AVP. Evidence, however, from clinical studies and animal models of CNS disorders has directly implicated disturbances in vasopressinergic activity in the pathophysiology of a number of human psychiatric disorders (mood, anxiety, and cognitive disorders). This review will examine the available evidence of central vasopressinergic system involvement in psychiatric disorders, and the potential opportunities for development of novel psychopharmaceuticals around this system will be discussed. Specific lines of evidence will be presented which rationalize each AVP receptor subtype (V1R or V1a, V2R, V3R or V1b) as a molecular target for particular psychiatric indications.
Export Options
About this article
Cite this article as:
Ring H. Robert, The Central Vasopressinergic System: Examining the Opportunities for Psychiatric Drug Development, Current Pharmaceutical Design 2005; 11 (2) . https://dx.doi.org/10.2174/1381612053382241
DOI https://dx.doi.org/10.2174/1381612053382241 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotection of Dietary Virgin Olive Oil on Brain Lipidomics During Stroke
Current Neurovascular Research Adiposity and Alzheimers Disease
Current Alzheimer Research Anti-inflammatory Effect of Predimenol, A Bioactive Extract from <i>Phaleria macrocarpa</i>, through the Suppression of NF-κB and COX-2
Recent Advances in Inflammation & Allergy Drug Discovery Metabolic Syndrome X is a Low-Grade Systemic Inflammatory Condition with its Origins in the Perinatal Period
Current Nutrition & Food Science The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours
Recent Patents on CNS Drug Discovery (Discontinued) Natural Endoperoxides as Drug Lead Compounds
Current Medicinal Chemistry Current Therapeutic Paradigms in Glioblastoma
Reviews on Recent Clinical Trials Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Growth Factors and Astrocytes Metabolism: Possible Roles for Platelet Derived Growth Factor
Medicinal Chemistry Surgical Treatment of the Sleep Apnea Syndrome in the Twenty-First Century
Current Respiratory Medicine Reviews Recent Patents and Emerging Therapeutics in the Treatment of Allergic Conjunctivitis
Recent Patents on Inflammation & Allergy Drug Discovery Biological Relevance of Lysophospholipids and Green Solutions for Their Synthesis
Current Organic Chemistry Conventional (Continuous) EEG Monitoring in the NICU
Current Pediatric Reviews Implications of the Molecular Basis of Prostacyclin Biosynthesis and Signaling in Pharmaceutical Designs
Current Pharmaceutical Design New Insights into Oxidative Damage and Iron Associated Impairment in Traumatic Brain Injury
Current Pharmaceutical Design Nano Traditional Chinese Medicine: Current Progresses and Future Challenges
Current Drug Targets Cornea and Ocular Surface Treatment
Current Stem Cell Research & Therapy Update Clinical Application of Diffusion Tensor Imaging
Current Medical Imaging Pharmacologic Treatment of Restless Legs Syndrome
Current Neuropharmacology Vasoactive Factors and Diabetic Retinopathy: Vascular Endothelial Growth Factor, Cycoloxygenase-2 and Nitric Oxide
Current Pharmaceutical Design